TL;DR — Krill oil delivers omega-3 EPA/DHA bound to phospholipids (mostly phosphatidylcholine) plus astaxanthin. Per gram it contains less EPA+DHA than fish oil, but the phospholipid form has ~50% higher bioavailabilityHow much of a compound actually reaches your bloodstream and tissues after you take it. Full glossary → per mg omega-3 (Ulven 2011 PMID 21688839). Small RCTs support lipid modification and mild joint benefit. Standard dose 1–3 g/day; more expensive than fish oil. Not a superior replacement, but a legitimate alternative for those who don't tolerate fish oil burps.
What krill oil does (and why it matters)
Krill (Euphausia superba) is a small crustacean at the base of the Antarctic marine food web. Krill oil differs from fish oil in three ways:
- Omega-3 in phospholipid form (fish oil is triglyceride form) — 30–50% higher bioavailability per mg
- Contains astaxanthin (~200 µg/g) — natural preservative + antioxidant
- Lower total omega-3 per gram (~200 mg EPA+DHA per 1 g krill oil vs ~300–400 mg per 1 g fish oil concentrate)
The phospholipid form matters because omega-3 fatty acids bound to phosphatidylcholine are absorbed directly across enterocyte membranes without needing digestive re-esterification, and are preferentially incorporated into red-cell membranes.
Primary hallmarks targeted: Chronic inflammation · Altered intercellular communication (membrane composition) · Deregulated nutrient sensing (metabolic)
Ulven et al. (2011, PMID 21688839) — 113 adults compared krill oil 3 g vs fish oil 3 g vs placebo × 7 weeks — krill oil raised omega-3 index similarly to fish oil despite ~40% lower EPA+DHA mass. Bunea et al. (2004, PMID 15656416) — 120 hyperlipidemic patients — krill oil 1–3 g/day for 3 months reduced LDL 32–39%, TG 27%, raised HDL 44–60%. Deutsch (2007, PMID 17439714) — 90 arthritis patients — krill oil 300 mg/day reduced WOMAC pain 28% and CRP by 30%. Krill oil trials are smaller than fish oil trials but consistent in direction.
Mechanism
| Pathway | Mechanism | Hallmark link |
|---|---|---|
| Phospholipid form absorption | Direct membrane incorporation; higher bioavailability | — |
| Membrane omega-3 index | Raises RBC EPA+DHA% (goal >8%) | Communication |
| Anti-inflammatory eicosanoids | EPA → resolvins, protectins (SPMs) | Inflammation |
| Lipid modulation | ↓ TG, ↑ HDL via LXR / PPARα | Nutrient sensing |
| Astaxanthin bonus | Lipophilic antioxidant | Mitochondrial |
The fish oil vs krill oil question: for pure omega-3 mass delivery, high-concentration fish oil (or algae-derived DHA/EPA for vegans) is cheaper. Krill's edge is (a) better absorption per mg, (b) astaxanthin content, (c) less GI upset / "fish burps" for many users, (d) sustainability concerns favor MSC-certified krill for some consumers.
When krill oil is worth choosing over fish oil
Krill oil (vs fish oil) is worth choosing when one or more apply:
- Chronic "fish oil burps" or GI upset with fish oil
- Preferring smaller total capsule burden (higher bioavailability per mg)
- Building an anti-inflammatory stack with visible improvement goal
- Elevated triglycerides + interest in astaxanthin's added benefit
Skip and use fish oil if cost is a concern (fish oil is 3–4× cheaper per mg omega-3), if you want the largest possible omega-3 dose (fish concentrate is denser), or if you're vegan (algae-derived DHA/EPA is the appropriate substitute).
Evidence summary
| Study | Design | N | Duration | Key outcomes | Tier |
|---|---|---|---|---|---|
| Ulven 2011 (PMID 21688839) | RCT (comparative) | 113 | 7 wk | Krill = fish oil for omega-3 index despite lower mass | B |
| Bunea 2004 (PMID 15656416) | RCT (hyperlipidemic) | 120 | 3 mo | ↓ LDL 32–39%, ↓ TG 27%, ↑ HDL | B |
| Deutsch 2007 (PMID 17439714) | RCT (arthritis) | 90 | 30 d | ↓ WOMAC pain 28%, ↓ CRP 30% | B |
| Skarpańska 2010 (PMID 20406627) | RCT (dyslipidemia) | 76 | 12 wk | Modest lipid improvements | C |
← Swipe for more columns →
Consensus: Tier B for lipid modification and omega-3 index improvement. Smaller-scale than fish oil trials but consistent. Not clearly superior for hard cardiovascular outcomes — those large trials haven't been done with krill oil.
Where krill oil disappoints
- The Bunea 2004 lipid effects look impressive but are much larger than most fish oil trials — likely reflects the specific patient population, not a general krill superiority. Later trials showed smaller effects. - Cost per mg omega-3 is 3–4× higher than fish oil concentrate. Bioavailability advantage doesn't fully close the gap. - Sustainability concerns — krill are the base of the Antarctic food web; MSC certification matters for ecological responsibility. - Shellfish allergy — krill are crustaceans; theoretical cross-reactivity.
Dosing protocol
| Parameter | Recommendation | Notes |
|---|---|---|
| Foundation / omega-3 index | 1–2 g/day (delivers ~200–400 mg EPA+DHA) | With meals |
| Lipid modification | 1–3 g/day divided | With meals |
| Joint / inflammatory (Deutsch) | 300 mg/day | Higher-quality preparation |
| Timing | With fat-containing meals | Improves absorption |
| Form | Superba, NKO, or MSC-certified krill | Verify astaxanthin content |
| Duration | 12+ weeks for omega-3 index changes | RBC turnover slow |
Monitoring
| Biomarker | Target | Frequency | Action if off-target |
|---|---|---|---|
| Omega-3 index (RBC EPA+DHA%) | > 8% | Baseline + 4 mo | Increase dose if <5% |
| Triglycerides | < 100 mg/dL | 3–6 months | Combined with dietary change |
| hs-CRP | < 1.0 mg/L | 3 months | Combined with lifestyle |
← Swipe for more columns →
Safety, red flags, and contraindications
- Well tolerated; GI upset less common than fish oil.
- Mild anticoagulant effect at high dose.
Do not self-start without clearance
- Shellfish allergy — theoretical cross-reactivity; consult allergist.
- On warfarin, DOACs, antiplatelets — additive bleeding risk with high dose.
- Scheduled surgery — discontinue 1 week before.
- Pregnancy — omega-3 is safe and beneficial; krill specifically has less established safety data than fish oil in pregnancy.
Synergies and antagonists
Pairs well with:
Works against / redundant with:
| Antagonist | Conflict | What to do |
|---|---|---|
| Concurrent fish oil at high dose | Redundant omega-3 delivery | Pick one primary source |
| Warfarin | Additive bleeding | Monitor INR |
References
Links open PubMed. TNiC does not sell supplements; citations support education, not medical advice.